Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025
A Jehovah's Witness with Acquired Hemophilia A Who Successfully Avoided Blood Transfusions by Receiving Emicizumab.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saito Makoto, Yasumoto Atsushi, Ieko Masahiro, Miyashita Naoki, Yokoyama Emi, Kanaya Minoru, Izumiyama Koh, Mori Akio, Morioka Masanobu, Kondo Takeshi
Аннотация
INTRODUCTION: Acquired hemophilia A (AHA) manifests as a significant deficiency in coagulation factor VIII (FVIII) activity caused by the development of autoantibodies against FVIII and results in severe bleeding symptoms that can be life-threatening. Therefore, patients with AHA often require blood transfusions. Emicizumab, a bispecific monoclonal antibody that replaces the function of activated FVIII, has been more widely used to treat AHA.
CASE PRESENTATION: We report a 70-year-old male Jehovah's Witness with AHA who refused blood transfusions despite experiencing severe bleeding in the left biceps muscle; anemia had progressed by 3 g/dL (hemoglobin level) in just 2 days. Since the use of coagulation factor products had been approved in writing, we administered a single-dose mixture of activated factor VIIa/X (Byclot®) and promptly achieved hemostasis. Subsequently, regular administration of emicizumab was effective in preventing rebleeding and successfully avoiding blood transfusions.
CONCLUSION: For Jehovah's Witnesses with AHA, the administration of emicizumab can be considered a highly valuable treatment.
CASE PRESENTATION: We report a 70-year-old male Jehovah's Witness with AHA who refused blood transfusions despite experiencing severe bleeding in the left biceps muscle; anemia had progressed by 3 g/dL (hemoglobin level) in just 2 days. Since the use of coagulation factor products had been approved in writing, we administered a single-dose mixture of activated factor VIIa/X (Byclot®) and promptly achieved hemostasis. Subsequently, regular administration of emicizumab was effective in preventing rebleeding and successfully avoiding blood transfusions.
CONCLUSION: For Jehovah's Witnesses with AHA, the administration of emicizumab can be considered a highly valuable treatment.